GSK GSK plc stock chart & analysis
Conviction 64HealthcareScan · Fri, Nov 6, 2026GSK plc (GSK) closed at $50.33 (-0.16%) on Nov 6, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 54, RS Rating 70, -18.4% from its 52-week high, +2.6% year to date. Sector: Healthcare · Drug Manufacturers - General.
GSK technical analysis
Trend
GSK's moving averages are mixed — no clean uptrend or downtrend. It closed 2.1% above the 50-day ($49.27) and 3.9% below the 200-day ($52.38). ADX(14) at 16 points to a weak trend — more range than direction. It meets 4 of 8 trend-template criteria.
Momentum
RSI(14) is 54, in the bullish half of its range. MACD crossed above its signal line 2 sessions ago. Its RS Rating of 70 puts its weighted 12-month performance ahead of about 70% of the US market.
Volume and volatility
Volume on the latest session ran 0.5× its 20-day average. It trades about $251.3M a day on average. ATR(14) is $1.27, 2.5% of price — its typical daily range.
Key levels
The chart pattern's support is $45.97 and its resistance $51.34. The 52-week range is $45.81 to $61.70; price is 18.4% below the high and 9.9% above the low. The VWAP anchored at the 52-week high is $52.15, above price.
Performance
GSK returned +1.6% (1 week), +8.1% (1 month), -3.5% (3 months), -0.2% (6 months), +7.8% (1 year), +2.6% (year to date).
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Drug Manufacturers - General · Listed 1976 · 66,841 employees
Recent news
- GSK plc: 6-K filedSEC EDGAR · Fri, Nov 6, 2026
Congress activity
Disclosed STOCK Act trades in GSK · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Lisa McClain house · MI · traded 2025-10-31 | Sell | $1K–$15K | 2025-10-31 | 2025-11-01 | |
Lisa McClain house · MI · traded 2025-10-30 | Sell | $1K–$15K | 2025-10-30 | 2025-11-01 | |
 Valerie Hoyle house · D · OR · traded 2025-09-23 | Sell | $1K–$15K | 2025-09-23 | 2025-10-10 | |
Valerie Hoyle house · D · OR · traded 2024-11-18 | Buy | $1K–$15K | 2024-11-18 | 2025-09-12 | |
Lisa McClain house · R · MI · traded 2025-08-04 | Buy | $1K–$15K | 2025-08-04 | 2025-09-12 | |
 Robert B. Aderholt house · R · AL · traded 2025-07-28 | Sell | $1K–$15K | 2025-07-28 | 2025-09-10 | |
Lisa McClain house · R · MI · traded 2025-06-24 | Sell | $1K–$15K | 2025-06-24 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-17 | Buy | $1K–$15K | 2025-06-17 | 2025-08-13 | |
 Bruce Westerman house · R · AR · traded 2025-04-21 | Sell | $1K–$15K | 2025-04-21 | 2025-05-12 | |
Bruce Westerman house · R · AR · traded 2025-03-03 | Buy | $1K–$15K | 2025-03-03 | 2025-04-16 |
SEC filings
EDGAR filings in GSK · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.